Who we are

Unleashing Our innovative Targeted Therapeutics Redefines Cancer Treatment

Who we are

Our team translates early-stage discoveries into clinical applications to make a significant impact in cancer treatment. We are committed to fighting cancer with our proprietary therapeutics, using advanced scientific knowledge in cancer biology and extensive expertise in drug development. With our unique approach targeting tumor-associated antigens, we aim to create potent and effective cancer treatments that meet the unmet needs of patients.

Meet our team

We have extensive hands-on expertise in drug development and growing biotechs. We have successfully nurtured start-ups, helping them become prominent players in the field, and sold to larger developers or merged with prominent players for further development and commercialization. Our objective is to continuously enhance the company’s overall value by consistently developing competitive drug candidates and capturing attention for partnerships.

MANAGEMENT TEAM

Hahn-Jun Lee, M.Sc., Ph.D.

CEO & Founder

BOARD OF DIRECTORS

Hahn-Jun Lee, M.Sc., Ph.D.

Chair of the Board

We transform scientific knowledge into precision medicines to eradicate cancer.

Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.

Contact us

© 2024 7 PRIMUS BIOSCIENCES

President/CEO

Hahn-Jun Lee, M.Sc., Ph.D.

Dr. Lee has extensive experience in establishing and growing biotech companies. He founded and grew biotechs such as Epygenix Therapeutics, Inc., a precision rare genetic epilepsy drug development company which has been acquired by Harmony Biosciences (NASDAQ: HRMY), and Polaryx Therapeutics, Inc., which specializes in patient-friendly treatments for Batten disease. Dr. Lee has also successfully advanced numerous early-stage discovery programs to the clinical stage, overseeing their progression from the laboratory to clinical trials. He has obtained multiple approvals from the US FDA, Health Canada, and MHRA for IND, ODD, and RPDD applications.

In addition to his entrepreneurial and proficient drug development expertise, Dr. Lee has vast experience in business development. He has worked with various venture capital firms, global pharmaceutical companies, and biotech companies, contributing to their business development endeavors.

Furthermore, he has held academic positions, including Assistant Professor of Biotechnology at the Department of Orthopedic Surgery in the College of Physicians and Surgeons of Columbia University in New York City, and Staff Scientist at the RIKEN Brain Science Institute in Japan. Dr. Lee earned his M.S. and Ph.D. in Applied Biotechnology from the University of Tokyo, Japan, and his B.S. in Life Science from Sogang University in Seoul, Korea.

Chair of Board of Directors

Hahn-Jun Lee, M.Sc., Ph.D.

Dr. Lee has extensive experience in establishing and growing biotech companies. He founded and grew biotechs such as Epygenix Therapeutics, Inc., a precision rare genetic epilepsy drug development company which has been acquired by Harmony Biosciences (NASDAQ: HRMY), and Polaryx Therapeutics, Inc., which specializes in patient-friendly treatments for Batten disease. Dr. Lee has also successfully advanced numerous early-stage discovery programs to the clinical stage, overseeing their progression from the laboratory to clinical trials. He has obtained multiple approvals from the US FDA, Health Canada, and MHRA for IND, ODD, and RPDD applications.

In addition to his entrepreneurial and proficient drug development expertise, Dr. Lee has vast experience in business development. He has worked with various venture capital firms, global pharmaceutical companies, and biotech companies, contributing to their business development endeavors.

Furthermore, he has held academic positions, including Assistant Professor of Biotechnology at the Department of Orthopedic Surgery in the College of Physicians and Surgeons of Columbia University in New York City, and Staff Scientist at the RIKEN Brain Science Institute in Japan. Dr. Lee earned his M.S. and Ph.D. in Applied Biotechnology from the University of Tokyo, Japan, and his B.S. in Life Science from Sogang University in Seoul, Korea.